Trials / Withdrawn
WithdrawnNCT04193930
Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles
Soft Versus Conventional Protocol in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles for Poor Responders
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Assiut University · Academic / Other
- Sex
- Female
- Age
- 40 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
During assisted reproduction technology treatments like in vitro fertilization, some patients give a poor ovarian response to controlled ovarian hyperstimulation. The European Society of Human Reproduction and Embryology consensus defined poor response to ovarian stimulation during in vitro fertilization with Bologna criteria. Bologna criteria: At least two of the following three features must be present: (i) Advanced maternal age (≥40 years). (ii) Previous Poor responders (≤3 oocytes with a conventional stimulation protocol). (iii) An abnormal ovarian reserve test Most controlled ovarian hyperstimulation regimens currently used for expected poor responders are based on using a high daily dose (300- 450 IU/day) of exogenous gonadotropins. Giving a high gonadotropin dose obviously increases the cost of in vitro fertilization, a consequence that would be acceptable if paralleled by an improvement in in vitro fertilization outcome. Unfortunately, however, the available data suggest that increasing the daily gonadotropins dose may increase the number of retrieved oocytes, but not the final success rate of in vitro fertilization.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Letrozole | Oral tablet letrozole 2,5 mg/twice daily for 5 days |
| DRUG | Menotropins | 150 IU of highly purified menotropins intramuscular |
| DRUG | recombinant Follicular stimulating hormone | recombinant Follicular stimulating hormone 300- 400 IU |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2021-01-01
- Completion
- 2021-01-01
- First posted
- 2019-12-10
- Last updated
- 2022-11-30
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04193930. Inclusion in this directory is not an endorsement.